[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100445135":3},{"organization":4,"armGroups":7,"interventions":34,"overallOfficials":40,"centralContacts":44,"locations":53,"responsibleParty":72,"collaborators":76,"id":79,"slug":80,"hasResults":81,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":81,"sex":86,"minAge":87,"maxAge":10,"enrollmentInfo":88,"targetDuration":10,"studyType":91,"phases":10,"briefSummary":92,"conditions":93,"keywords":10,"overallStatus":56,"whyStopped":10,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},{"fullName":5,"class":6},"University of Manchester","OTHER",[8,14,18,22,26,30],{"label":9,"type":10,"description":11,"interventionNames":12},"Cervical cancer",null,"Cervical cancer patients receiving standard of care radiotherapy",[13],"Procedure: Biopsy and blood sample collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Rectal cancer","Rectal cancer patients receiving standard of care radiotherapy",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Head and neck cancer","Head and neck cancer patients receiving standard of care radiotherapy",[13],{"label":23,"type":10,"description":24,"interventionNames":25},"nodal non-Hodgkin lymphoma","Patients with nodal NHL receiving standard of care radiotherapy",[13],{"label":27,"type":10,"description":28,"interventionNames":29},"cutaneous lymphoma","Patients with cutaneous lymphoma receiving standard of care radiotherapy",[13],{"label":31,"type":10,"description":32,"interventionNames":33},"cutaneous squamous cell carcinoma and basal cell carcinoma","Patients with cSCC and cBCC receiving standard of care radiotherapy",[13],[35],{"type":36,"name":37,"description":38,"armGroupLabels":39,"otherNames":10},"PROCEDURE","Biopsy and blood sample collection","A pre-treatment diagnostic biopsy sample plus 1 mandatory biopsy (during\u002Fpost-radiotherapy \\[irradiated site\\]) will be collected from each participant.\n\nMatched blood samples will be collected from participants at baseline, during\u002Fpost-radiotherapy, and if radiotherapy continues after the on-treatment biopsy is taken, an additional end of treatment blood sample will be collected.",[9,19,15,27,31,23],[41],{"name":42,"affiliation":5,"role":43},"Timothy M Illidge","STUDY_CHAIR",[45,50],{"name":46,"role":47,"phone":48,"phoneExt":10,"email":49},"Lois Gardner","CONTACT","01612008863","lois.gardner@manchester.ac.uk",{"name":51,"role":47,"phone":48,"phoneExt":10,"email":52},"Eleanor Cheadle","eleanor.j.cheadle@manchester.ac.uk",[54],{"facility":55,"status":56,"city":57,"state":10,"zip":58,"country":59,"countryCode":60,"cosmosGeoPoint":61,"geoPoint":66,"contacts":67},"Christie NHS Foundation Trust","RECRUITING","Manchester","M20 4BX","United Kingdom","UK",{"type":62,"coordinates":63},"Point",[64,65],-2.23743,53.48095,{"lat":65,"lon":64},[68],{"name":69,"role":47,"phone":70,"phoneExt":10,"email":71},"Catherine Trigwell","01613066088","catherine.trigwell@manchester.ac.uk",{"type":73,"investigatorFullName":74,"investigatorTitle":75,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Tim Illidge","Professor of Targeted Therapy and Oncology",[77],{"name":78,"class":6},"The Christie NHS Foundation Trust","100445135","investigating-the-tumour-immune-response-of-radiotherapy-100445135",false,"NCT05076500","Investigating the Tumour Immune Response of Radiotherapy","TIMM-RAD","Inclusion Criteria:\n\n* Histologically confirmed cancer, Stage I-IV, in one of the following: Cervical, rectal, nodal Non-Hodgkin lymphoma, cutaneous lymphoma, Head \\& neck cancer\n* Diagnostic\u002Fpre-treatment biopsy confirmed suitable for translational research \\*\n* Performance status - ECOG 0-2 (Refer to appendix 1), ECOG 3 allowed for arm F (unrelated to underlying cancer) as this group of patients often have ECOG 3 due to age and comorbidities.\n* Age ≥ 18; no upper age limit.\n* Participant considered suitable for radiotherapy\n* Before participant registration, written informed consent must be given according to GCP and national regulations.\n\n  \\*Pre-treatment biopsy must be from the gross tumour volume within the planned radiation field and must also:\n* Have been formalin fixed for \\>12h and \\\u003C72h\n* Have tumour tissue and morphology confirmed by H\\&E staining\n* Contain sufficient tumour cells (approximately 100)\n\nExclusion Criteria:\n\n* Participants deemed unsuitable for a biopsy (during or following radiotherapy) in the opinion of the treating oncologist.\n* Participants who have received chemotherapy within 28 days of starting radiotherapy.\n* Participants with intercurrent or past history of hepatitis B, C or human immunodeficiency virus infection if known. A negative test result for hepatitis B, C and HIV infection is required prior to inclusion in the study.","ALL","18 Years",{"count":89,"type":90},120,"ESTIMATED","OBSERVATIONAL","This study aims to investigate immune changes which occur before and following standard radiotherapy in a range of tumour types. We will collect tissue and blood samples before and after radiation treatment from participants across six cancer types: cervical, rectal, Head and Neck cancer, nodal non-Hodgkin lymphoma, cutaneous lymphoma and cutaneous squamous cell carcinoma\u002F basal cell carcinoma.",[94],"Cancer","2025-06-05",{"date":97,"type":98},"2025-06-11","ACTUAL",{"date":100,"type":98},"2021-07-14",{"date":102,"type":90},"2026-08-14",{"name":5,"class":6},1]